Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials

Table 2 Pharmacokinetic parameters after a single subcutaneous administration of ozoralizumab

Dose (mg)	N	C_max (μg/mL)	t_max (h)	AUC_0-last (h·μg/mL)	AUC_0-∞ (h·μg/mL)	t_1/2 (day)	CL/F (mL/h)	V_d/F (L)
30	77	4.55 ± 1.18	144 (23.2–336)	2050 ± 523	3280 ± 1280^a	18.2 ± 8.21^a	10.4 ± 3.91^a	5.88 ± 1.72^a
80	80	12.5 ± 2.84	144 (22.1–212)	5540 ± 1080	8860 ± 3010	17.9 ± 5.98	9.92 ± 2.93	5.71 ± 1.09

Data are expressed as mean ± standard deviation or median (range)
AUC area under the plasma concentration–time curve, AUC_0-∞ AUC from 0 to infinity, AUC_0-last AUC from 0 to the last quantifiable data point, CL/F apparent clearance, C_max maximum concentration, t_1/2 elimination half-life, t_max time to maximum concentration, V_d/F apparent volume of distribution
^aN = 74

ISSN: 1478-6362